The NIC 2015 Capital & Business Strategies forum takes place Tuesday through Thursday in San Diego, with keynote speakers including Kathleen Sebelius, Katy Fike and Bruce Chernof.
Dude Solutions acquires Windmill Software
Mar 25, 2015
Dude Solutions Inc., a software-as-a-service provider, has bought Windmill Software Inc., including its flagship senior living operations software, TheWorxHub.
Guardian Pharmacy adds EPS, Patient Care Pharmacy Services
Mar 24, 2015
Guardian Pharmacy LLC has added Extensive Pharmaceutical Services of Kinston, NC, and Patient Care Pharmacy Services of Port Charlotte, FL.
KeyBank provides $93.75M in loans
Mar 24, 2015
KeyBank Real Estate Capital has provided $93.75 million in Fannie Mae loans to finance a portfolio of four assisted living communities on behalf of NorthStar Healthcare Income Inc., the company announced....
Granite Investment announces AL buy
Mar 24, 2015
Granite Investment Group has acquired a 48-unit assisted living facility in the Kansas City suburb of Shawnee, KS.
RTMS launches new website
Mar 18, 2015
Real Time Medical Systems has created a new website and announced a rebranding of its corporate and product identities.
Managed Health Care Associates rolls out CTM software
Mar 18, 2015
Managed Health Care Associates Inc. announced the rollout of its full Clinical Therapy Management patient management software system for pharmacy and infusion providers.
RAC beats CMS on payment lawsuit appeal
By
John Hall
Mar 16, 2015
A federal appeals court last week ruled that the Centers for Medicare & Medicaid Services violated federal contracting regulations when it stretched out payment terms for recovery audit contractors.
Owner of two nursing agencies charged with $5 million Medicare fraud
By
John Hall
Mar 12, 2015
The owner of two Illinois nursing agencies was arrested Tuesday on charges he allegedly defrauded Medicare out of more than $5 million for unnecessary home care services over a 44-month period. The arrest...
FDA panel approves first biosimilar drug
Mar 10, 2015
The Food and Drug Administration approved its first biosimilar product last week, opening the door for more costly drug alternatives.